Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
ZimVie Inc ( (ZIMV) ) has provided an announcement.
On October 20, 2025, ZimVie Inc. announced the completion of its acquisition by ARCHIMED, an investment firm focused on healthcare industries. As a result of the acquisition, ZimVie has become a privately held company, and its common stock is no longer traded on the NASDAQ stock exchange. ZimVie stockholders are entitled to receive $19.00 in cash per share. The acquisition is expected to accelerate ZimVie’s growth as a global leader in the dental implant market, with ARCHIMED providing strategic and financial support.
The most recent analyst rating on (ZIMV) stock is a Hold with a $19.00 price target. To see the full list of analyst forecasts on ZimVie Inc stock, see the ZIMV Stock Forecast page.
Spark’s Take on ZIMV Stock
According to Spark, TipRanks’ AI Analyst, ZIMV is a Neutral.
ZimVie Inc.’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and persistent losses. The technical analysis suggests bullish momentum, but overbought indicators may lead to a pullback. Valuation concerns, including a negative P/E ratio and lack of dividend yield, further weigh down the score.
To see Spark’s full report on ZIMV stock, click here.
More about ZimVie Inc
ZimVie is a global life sciences leader in the dental implant market, developing, manufacturing, and delivering a comprehensive portfolio of products and solutions for dental tooth replacement and restoration procedures. The company is headquartered in Palm Beach Gardens, Florida, with additional facilities worldwide, and is committed to advancing clinical science and technology in dental care.
Average Trading Volume: 723,851
Technical Sentiment Signal: Buy
Current Market Cap: $535.7M
For detailed information about ZIMV stock, go to TipRanks’ Stock Analysis page.